<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Thyrotoxicosis; Antithyroid drugs; Thyroid: antagonists; Thyroidectomy; Carbimazole; Propylthiouracil; Iodine: thyrotoxicosis; Iodine: radioactive; Beta-adrenoceptor blocking drugs: thyrotoxicosis; Thyrotoxicosis: beta-blockers; Propranolol: thyrotoxicosis; Hyperthyroidism see Thyrotoxicosis; Nadolol: thyrotoxicosis; Thyroid: storm; Thyrotoxic crisis" /><meta name="IX" content="Thyrotoxicosis; Antithyroid drugs; Thyroid: antagonists; Thyroidectomy; Carbimazole; Propylthiouracil; Iodine: thyrotoxicosis; Iodine: radioactive; Beta-adrenoceptor blocking drugs: thyrotoxicosis; Thyrotoxicosis: beta-blockers; Propranolol: thyrotoxicosis; Nadolol: thyrotoxicosis; Thyroid: storm; Thyrotoxic crisis" /><meta name="IXN" content="Hyperthyroidism see Thyrotoxicosis" /><title>6.2.2 Antithyroid drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="4242.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="4242.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=4242.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2073.htm">6 Endocrine system</a> &gt; <a href="4235.htm">6.2 Thyroid and antithyroid drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4239.htm" title="Previous: LIOTHYRONINE SODIUM">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="4243.htm" title="Next: CARBIMAZOLE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_4242">6.2.2 Antithyroid drugs</h1><?highlighter on?><div id="pC" class="jN"><div><p>Antithyroid drugs are
used for hyperthyroidism either to prepare patients for thyroidectomy or for long-term
management. In the UK <b>carbimazole</b> is the most commonly
used drug. <b>Propylthiouracil</b> should be reserved for
patients who are intolerant of carbimazole or for those who experience
sensitivity reactions to carbimazole (sensitivity is not necessarily
displayed to both drugs), and for whom other treatments are inappropriate.
Both drugs act primarily by interfering with the synthesis of thyroid
hormones.</p><div id="_4242.2"><div class="cN"><h3 class="cBP">Neutropenia and agranulocytosis</h3><p>Doctors are reminded of the importance of recognising bone marrow
suppression induced by <span>carbimazole</span> and the need
to stop treatment promptly.</p><ol class=""><li><p class="cQ">Patient should be asked to report symptoms
and signs suggestive of infection, especially sore throat.</p></li><li><p class="cQ">A white blood cell count should be performed
if there is any clinical evidence of infection.</p></li><li><p class="cQ"><span>Carbimazole</span> should be
stopped promptly if there is clinical or laboratory evidence of neutropenia.</p></li></ol></div></div><p><b><span>Carbimazole</span></b> is given in a dose
of 15 to 40 mg daily; higher doses should be prescribed under specialist
supervision only. This dose is continued until the patient becomes
euthyroid, usually after 4 to 8 weeks and the dose is then gradually
 reduced to a maintenance dose of 5 to 15 mg. Therapy is usually given
for 12 to 18 months. Treatment in children should be
undertaken by a specialist, see <i><a href="http://www.medicinescomplete.com/mc/bnfc/current/4243.htm" title="BNFC:monograph: CARBIMAZOLE">BNF for Children</a></i>. Rashes and pruritus
are common but they can be treated with antihistamines without discontinuing
therapy; alternatively propylthiouracil can be substituted. All patients should be advised to report any sore throat immediately because of the rare complication of agranulocytosis (see Neutropenia
and Agranulocytosis, above).</p><div id="_213860"><p><b><span>Propylthiouracil</span></b> is given in a dose of 200 to
400 mg daily in divided doses in adults and this dose is maintained
until the patient becomes euthyroid; the dose may then be gradually
reduced to a maintenance dose of 50 to 150 mg daily in divided doses.</p><p>Over-treatment with antithyroid drugs can result in the rapid
development of hypothyroidism and should be avoided particularly during pregnancy because it can cause fetal goitre.</p><p>A combination of <span>carbimazole</span>, 40 to 60 mg
daily with levothyroxine, 50 to 150 micrograms daily, may be used
in a <i>blocking-replacement regimen</i>; therapy is usually
given for 18 months. The blocking-replacement regimen is <b>not</b> suitable during pregnancy.</p></div><p><b>Iodine</b> has been used as an adjunct to antithyroid
drugs for 10 to 14 days before partial thyroidectomy; however, there
is little evidence of a beneficial effect. Iodine should not be used
for long-term treatment because its antithyroid action tends to diminish.</p><p>Radioactive
sodium iodide (<sup>131</sup>I) solution is used increasingly for
the treatment of thyrotoxicosis at all ages, particularly where medical
therapy or compliance is a problem, in patients with cardiac disease,
and in patients who relapse after thyroidectomy.</p><p><b>Propranolol </b>is useful for rapid relief of thyrotoxic
symptoms and may be used in conjunction with antithyroid drugs or
as an adjunct to radioactive iodine. Beta-blockers are also useful
in neonatal thyrotoxicosis and in supraventricular arrhythmias due
to hyperthyroidism. Propranolol has been used in conjunction with
iodine to prepare mildly thyrotoxic patients for surgery but it is
preferable to make the patient euthyroid with <span>carbimazole</span>. Laboratory tests of thyroid function are not altered by beta-blockers.
Most experience in treating thyrotoxicosis has been gained with propranolol
but <b><span>nadolol</span></b> is also used. For doses and preparations
of beta-blockers see <a title=" Beta-adrenoceptor blocking drugs" href="2455.htm#_2455">section 2.4</a>.</p><p><i>Thyrotoxic crisis</i> (‘thyroid storm’) requires emergency treatment with intravenous
administration of fluids, propranolol (5 mg) and <span>hydrocortisone</span> (100 mg every 6 hours, as sodium succinate), as well as oral iodine
solution and <span>carbimazole</span> or <span>propylthiouracil</span> which may need to be administered by nasogastric tube.</p><div id="_4242.1"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">Radioactive iodine therapy is contra-indicated
during pregnancy. <span>Propylthiouracil</span> and <span>carbimazole</span> can be given but the blocking-replacement regimen
(see above) is <b>not</b> suitable. Rarely, <span>carbimazole</span> has been associated with congenital defects, including aplasia cutis
of the neonate, therefore propylthiouracil remains the drug of choice
during the first trimester of pregnancy. In the second trimester,
consider switching to carbimazole because of the potential risk of
hepatotoxicity with propylthiouracil. Both <span>propylthiouracil</span> and <span>carbimazole</span> cross the placenta
and in high doses may cause fetal goitre and hypothyroidism—the lowest
dose that will control the hyperthyroid state should be used (requirements
in Graves’ disease tend to fall during pregnancy). </p></div></div><div id="_215390"><div class="cAZ"><h2>Breast-feeding</h2> <p class="cAX"><span>Carbimazole</span> and <span>propylthiouracil</span> are present in breast milk but this does
not preclude breast-feeding
as long as neonatal development is closely monitored and the lowest
effective dose is used.</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_4243"><a href="4243.htm" title="CARBIMAZOLE">CARBIMAZOLE</a></li><li id="_4245"><a href="4245.htm" title="IODINE AND IODIDE">IODINE AND IODIDE</a></li><li id="_4247"><a href="4247.htm" title="PROPYLTHIOURACIL">PROPYLTHIOURACIL</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4239.htm">Previous: LIOTHYRONINE SODIUM</a> | <a class="top" href="4242.htm#">Top</a> | <a accesskey="]" href="4243.htm">Next: CARBIMAZOLE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>